H.M. Pharma Consultancy’s drug repurposing expertise continues to draw attention. See the recent interview by Pharmtech.com here. Among the high points: our Discontinued Drug and Candidate Database (DDCD) reference tool; the untapped potential of CROs in drug repurposing collaborations; and the business models that we are seeing.
In other matters, Mary Ann Liebert, Inc. has re-published the final issue of Drug Repurposing, Rescue, and Repositioning in its PubMed-listed journal, ASSAY and Drug Development Technologies (table of contents). The original full papers are as follows:
# Overington: Computational and Practical Aspects of Drug Repositioning
# Kathwate, Shinde & Karuppayi: Antiepileptic Drugs Inhibit Growth, Dimorphism, and Biofilm Mode of Growth in Human Pathogen Candida albicans
# Ianni et al.: Computer-Aided Identification of Anticonvulsant Effect of Natural Nonnutritive Sweeteners Stevioside and Rebaudioside A
# Mucke & Mucke: Sources and Targets for Drug Repurposing: Landscaping Transitions in Therapeutic Space
In addition, you will find our drug repurposing patent analyses for documents published by the PCT Office between October 2014 and March 2015. These reviews will continue in ASSAY.